Your browser doesn't support javascript.
loading
Structure-Activity Relationship Studies of Substituted 2-Phenyl-1,2,4-triazine-3,5(2H,4H)-dione Analogues: Development of Potent eEF2K Degraders against Triple-Negative Breast Cancer.
Zhao, Xiaobao; Zhong, Changxin; Zhu, Rongfeng; Gong, Rong; Liu, Bingyan; He, Linhao; Tian, Sheng; Jin, Jing; Jiang, Ting; Chen, Jing-Lei; Wan, Xiaoya; Liu, Wenjing; Jiang, Shilong; Deng, Pan; Cheng, Yan; Ye, Na.
Affiliation
  • Zhao X; Department of Medicinal Chemistry, Jiangsu Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China.
  • Zhong C; Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha 410011, China.
  • Zhu R; Hunan Provincial Engineering Research Centre of Translational Medicine and Innovative Drug, Changsha 410011, China.
  • Gong R; Department of Medicinal Chemistry, Jiangsu Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China.
  • Liu B; Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha 410011, China.
  • He L; Hunan Provincial Engineering Research Centre of Translational Medicine and Innovative Drug, Changsha 410011, China.
  • Tian S; Department of Medicinal Chemistry, Jiangsu Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China.
  • Jin J; Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha 410011, China.
  • Jiang T; Hunan Provincial Engineering Research Centre of Translational Medicine and Innovative Drug, Changsha 410011, China.
  • Chen JL; Department of Medicinal Chemistry, Jiangsu Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China.
  • Wan X; Jiangsu Province Engineering Research Center of Precision Diagnostics and Therapeutics Development, Soochow University, Suzhou 215123, China.
  • Liu W; Department of Medicinal Chemistry, Jiangsu Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China.
  • Jiang S; Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha 410011, China.
  • Deng P; Hunan Provincial Engineering Research Centre of Translational Medicine and Innovative Drug, Changsha 410011, China.
  • Cheng Y; Department of Medicinal Chemistry, Jiangsu Key Laboratory of Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Soochow University, Suzhou 215123, China.
  • Ye N; Department of Pharmacy, The Second Xiangya Hospital, Central South University, Changsha 410011, China.
J Med Chem ; 67(17): 15837-15861, 2024 Sep 12.
Article in En | MEDLINE | ID: mdl-39208364
ABSTRACT
eEF2K, an atypical alpha-kinase, is responsible for regulating protein synthesis and energy homeostasis. Aberrant eEF2K function has been linked to various human cancers, including triple-negative breast cancer (TNBC). However, limited cellular activity of current eEF2K modulators impedes their clinical application. Based on the 2-phenyl-1,2,4-triazine-3,5(2H,4H)-dione scaffold of our hits I4 and C1, structure-activity relationship analysis led to the discovery of several more active derivatives (e.g., 19, 34, and 36) in inhibiting the viability of TNBC cell line MDA-MB-231. Moreover, the most potent compound 36 significantly suppresses the viability, proliferation, and migration of both MDA-MB-231 and HCC1806 cell lines. Mechanistically, compound 36 has a high binding affinity for the eEF2K protein and effectively induces its degradation. Additionally, 36 exerts a comparable tumor-suppressive effect to paclitaxel in an MDA-MB-231 cell xenograft mouse model with no obvious toxicity, demonstrating that compound 36 could be developed as a potential novel therapeutic for TNBC treatment.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Triazines / Cell Proliferation / Elongation Factor 2 Kinase / Triple Negative Breast Neoplasms / Antineoplastic Agents Limits: Animals / Female / Humans Language: En Journal: J Med Chem Journal subject: QUIMICA Year: 2024 Document type: Article Affiliation country: China Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Triazines / Cell Proliferation / Elongation Factor 2 Kinase / Triple Negative Breast Neoplasms / Antineoplastic Agents Limits: Animals / Female / Humans Language: En Journal: J Med Chem Journal subject: QUIMICA Year: 2024 Document type: Article Affiliation country: China Country of publication: United States